Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Market Closed 05-15 16:00:00 EDT

7.47

-0.36

-4.60%

盘后7.47

+0.000.00%

18:26 EDT

High7.78	Low7.40	Vol548.28K
Open7.71	D1 Closing7.83	Amplitude4.85%
Mkt Cap212.24M	Tradable Cap196.28M	Total Shares28.41M
T/O4.11M	T/O Rate2.09%	Tradable Shares26.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":7.47,"timestamp":1778875200000,"preClose":7.83,"halted":0,"volume":548284,"hourTrading":{"tag":"盘后","latestPrice":7.47,"preClose":7.47,"latestTime":"18:26 EDT","volume":1261,"amount":9420.19,"timestamp":1778883990225,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.045977011494252915,"floatShares":26275300,"shares":28412537,"eps":-2.83921,"marketStatus":"Market Closed","change":-0.36,"latestTime":"05-15 16:00:00 EDT","open":7.71,"high":7.78,"low":7.4,"amount":4109947.9941652,"amplitude":0.048531,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.83921,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.83,"preHourTrading":{"tag":"盘前","latestPrice":7.9242,"preClose":7.83,"latestTime":"08:23 EDT","volume":495,"amount":3936.6625815,"timestamp":1778847821912,"change":0.0942,"changeRate":0.012031,"amplitude":0.057816},"postHourTrading":{"tag":"盘后","latestPrice":7.47,"preClose":7.47,"latestTime":"18:26 EDT","volume":1261,"amount":9420.19,"timestamp":1778883990225,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.904471,"impliedVol":0.7379,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/ARCT","defaultTab":"news","newsList":[{"id":"2635858347","title":"ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2635858347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635858347?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:36","pubTimestamp":1778668584,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein has maintained their neutral stance on ARCT stock, giving a Hold rating on May 11. Andrew Fein has given his Ho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arct-rating-reiterated-at-hold-as-high-risk-arct-032-cf-program-awaits-binary-phase-2-readout-9-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arct-rating-reiterated-at-hold-as-high-risk-arct-032-cf-program-awaits-binary-phase-2-readout-9-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","CF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213125","title":"Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213125","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213125?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:26","pubTimestamp":1778581605,"startTime":"0","endTime":"0","summary":"As you might know, Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) recently reported its first-quarter numbers...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings/news/arcturus-therapeutics-holdings-inc-nasdaqarct-consensus-fore","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings/news/arcturus-therapeutics-holdings-inc-nasdaqarct-consensus-fore","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQA","MNQmain","QQQY","FTEC","ARCT","TQQY","NVIW.SI",".IXIC","TQQQ","TECS","QLD","NDX","GPIQ","QQQM","QDTE","QID","JEPQ","QQQJ","NQmain","IYW","ONEQ","QQQ","QQQE","SQQQ","QYLG","BK4139","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633510533","title":"Arcturus Therapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633510533","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633510533?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:44","pubTimestamp":1778193856,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings SummaryArcturus Therapeutics Holdings Inc ARCT.OQ reported a quarterly adjusted loss of 95 cents per share ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633771641","title":"Arcturus Therapeutics Holdings Inc - Appoints Dennis Mulroy as CFO Effective May 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633771641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633771641?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:02","pubTimestamp":1778187733,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K1FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633174255","title":"Arcturus Therapeutics CFO Dennis Mulroy files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633174255","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633174255?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:33","pubTimestamp":1778186031,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics filed an initial Form 3 for Dennis Mulroy in his role as chief financial officer, dated May 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLWkB8s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633399176","title":"Arcturus Q1 FY26 net loss widens to $27 million; revenue drops to $2.06 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633399176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633399176?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:02","pubTimestamp":1778184173,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics posted a net loss of $27 million, or  per share, for the quarter ended March 31, 2026, versus a net loss of $14.1 million, or  per share, a year earlier.Revenue slid to $2.1 million from $29.4 million, driven by lower collaboration revenue as it pivots from infectious disease vaccine development toward rare disease clinical programs.Total operating expenses fell to $31 million from $46.2 million, with R&D dropping to $21.5 million from $34.9 million on lower LUNAR-COVID and BARDA manufacturing and trial costs.Cash, cash equivalents and restricted cash were $213.4 million at March 31, down from $232.8 million at end-2025, with cash runway expected to extend beyond second-quarter 2028.Initiated enrollment in a 12-week open-label Phase 2 study of inhaled CF candidate ARCT-032, while FDA provided Type C meeting direction for pediatric development of OTC deficiency program ARCT-810 ahead of an end-of-Phase 2 meeting planned for H2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL864v2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633763951","title":"BRIEF-Arcturus Therapeutics Q1 Net Income USD -26.964 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633763951","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633763951?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184107,"startTime":"0","endTime":"0","summary":"BRIEF-Arcturus Therapeutics Q1 Net Income USD -26.964 Million\n\n\nMay 07 (Reuters) - Arcturus Therapeutics Q1 collaboration revenue USD 610 thousand.\n\nQ1 operating income USD -28.931 million\nQ1 basic EPS USD -0.95\nQ1 operating expenses USD 30.992 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXE9A04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633252175","title":"Arcturus Therapeutics Q1 Collaboration Revenue USD 610 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2633252175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633252175?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXE9A04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117886","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117886","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117886?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Ares Comm. RE                                   1Q       .07    6:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKAM","AGO","ARW","ARHS","ARWR","ACMR","ASMB","ASTH","BBDC","ARCT","ALTG","AAON","AVNT","ALT","ASND","ARTV","AMN","ARGX","ARLO","AVPT","AKBA","AHR","ALRM","ANAB","ATLC","BBIO","AMPX","ACIW","AAOI","AMPH","DDOG","APPN","ASC","AFCG","ACRE","ALGM","ASPN","AURA","AFRM","AORT","BKV","AMLX","ACHR","APYX","ACLS","ABX","AMTX","ABSI","ABNB","ATHM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633764926","title":"Arcturus Therapeutics Holdings Inc  expected to post a loss of $1.09 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633764926","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633764926?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:13","pubTimestamp":1778012001,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc  expected to post a loss of $1.09 a share - Earnings Preview Arcturus Therapeutics Holdings Inc ARCT.OQ ARCT.O is expected to  show a fall in quarterly revenue when ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I35D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331244","title":"Arcturus Therapeutics updates financial calendar with first-quarter results conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331244?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:01","pubTimestamp":1777320074,"startTime":"0","endTime":"0","summary":"Arcturus to release first-quarter 2026 financial results May 7.Conference call, webcast set for May 7 at 4:30 p.m. ET via .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDLcd0RXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630312230","title":"Press Release: Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630312230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630312230?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:01","pubTimestamp":1777320060,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. , a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026.Arcturus Therapeutics First Quarter 2026 Earnings Conference Call","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARCT","BK4022","BK4232","BK4139","IE0009354923.USD","BK4585","R","RNA","LENZ","BK4539","CF","BK4588","BK4505","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630822215","title":"Arcturus Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630822215","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630822215?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:06","pubTimestamp":1777061188,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics set June 5, 2026 for its virtual annual shareholder meeting.Shareholders will vote on election of eight director nominees, including Moncef Slaoui and Joseph Payne.Agenda includes advisory vote on named executive officer compensation.Meeting will also consider ratification of Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDLc6VDF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627422906","title":"Roth MKM Remains a Buy on Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627422906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627422906?lang=en_us&edition=fundamental","pubTime":"2026-04-15 05:18","pubTimestamp":1776201505,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Adam Walsh reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $20.00. Walsh covers the Healthcare se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-remains-a-buy-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-remains-a-buy-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4588","BK4139","BK4585","LABU","XBI","BK4581","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622224892","title":"Roth MKM Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622224892","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622224892?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:55","pubTimestamp":1774565728,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Adam Walsh reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $20.00. Walsh covers the Healthcare se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620533842","title":"Arcturus Therapeutics Holdings Inc : B. Riley Initiates Coverage With Buy Rating; Price Target $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2620533842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620533842?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:03","pubTimestamp":1773835392,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN40613X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620623981","title":"Arcturus Therapeutics initiated with a Buy at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2620623981","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620623981?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:05","pubTimestamp":1773824717,"startTime":"0","endTime":"0","summary":"B. Riley initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $22 price target The firm says the company “stands out” given its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ARCT","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620238304","title":"U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238304?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:36","pubTimestamp":1773819417,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Factset, Lensar, StarbucksMarch 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, including Fa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4060HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107671.USD","STZ","ALDX","DC","AJG","CLH","CE","GEMI","GLXU","CADL","ANDG","DOCU","CRC","DOW","BL","ASO","CALM","FDS","CCL","BKKT","DTE","IE00BMG7P926.USD","GLGG","APD","EQIX","XYZY","BTSG","CTMX","DUOL","GEMG","LU1992135472.HKD","APGE","GLXY","BTGO","CLYM","LU1923621640.USD","DLR","FICO","ECL","ETR","GHM","XYZ","CF","XYZG","COHX","EVMN","ANRO","COHR","ARCT","HQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617528052","title":"Arcturus Therapeutics to Join Leerink Partners 2026 Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2617528052","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617528052?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:01","pubTimestamp":1772719319,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire  on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL15HMXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139","MNSH","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617518753","title":"Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2617518753","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617518753?lang=en_us&edition=fundamental","pubTime":"2026-03-05 14:00","pubTimestamp":1772690441,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) has disclosed a new risk, in the Regulation category. Arcturus Therapeutics faces heightened uncertainty as evolving U...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-shifts-cloud-arcturus-therapeutics-outlook-as-fda-delays-kostaive-bla-and-demands-new-covid-19-efficacy-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-shifts-cloud-arcturus-therapeutics-outlook-as-fda-delays-kostaive-bla-and-demands-new-covid-19-efficacy-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4535","BNTX","BK4548","BK4588","BK4551","LENZ","BK4585","ARCT","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":-0.1202},{"period":"1month","weight":-0.0979},{"period":"3month","weight":0.086},{"period":"6month","weight":0.077},{"period":"1year","weight":-0.2777},{"period":"ytd","weight":0.2773}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0773},{"period":"3month","weight":0.0974},{"period":"6month","weight":0.1135},{"period":"1year","weight":0.2733},{"period":"ytd","weight":0.0972}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.084619},{"month":2,"riseRate":0.538462,"avgChangeRate":0.016903},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.051078},{"month":4,"riseRate":0.615385,"avgChangeRate":0.111259},{"month":5,"riseRate":0.538462,"avgChangeRate":0.080623},{"month":6,"riseRate":0.615385,"avgChangeRate":0.024246},{"month":7,"riseRate":0.538462,"avgChangeRate":0.096382},{"month":8,"riseRate":0.538462,"avgChangeRate":0.072518},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.052457},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.077832},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033635},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.064746}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction